Neuro3d Identifies Candidate Compound and Extends Collaboration

22-Jul-2004

Neuro3d, a biopharmaceutical company focused on drug discovery and development, announced today that Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) in Beerse, Belgium, has identified a compound for further characterization from Neuro3d's propriety libraries and has extended the research collaboration with Neuro3d.

"The identification of this compound and extension of the research collaboration by J&JPRD further highlights the strength of Neuro3d's internal drug discovery capabilities. As this achievement is outside the psychiatric arena which is our main area of focus, we are now demonstrating the ability to leverage our expertise into other indications," noted Charles Woler, CEO of Neuro3d. "We look forward to the continued success of our collaboration with J&JPRD."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances